Skip to main content
Black Friday Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Summary by WFMZ
Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models

3 Articles

WFMZWFMZ
Center

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models

·Pennsylvania, United States
Read Full Article
Laotian TimesLaotian Times

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ — Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader PIN-5018 in a Phase 1 clinical trial. The first patient […]

Read Full Article
Eastern ProgressEastern Progress

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WFMZ broke the news in Pennsylvania, United States on Monday, November 24, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Richmond, Kentucky icon

Richmond, Kentucky

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal